Welcome to our dedicated page for MEDICURE SEC filings (Ticker: MCUJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MEDICURE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MEDICURE's regulatory disclosures and financial reporting.
Medicure Inc. files its Form 20-F annual report, outlining a Canada-based specialty pharma business focused on cardiovascular drugs and U.S. pharmacy operations. As of December 31, 2025, it had 10,436,313 common shares outstanding and reports in Canadian dollars, with US $1.00 equal to CND $1.3706.
Revenue is concentrated in AGGRASTAT, which still contributed about 20% of total revenue, alongside ZYPITAMAG and three U.S. pharmacies (Marley Drug, Gateway Pharmacy, West Olympia Pharmacy). ZYPITAMAG generated US $6.5 million in 2024 revenue, slightly above the prior year, but uptake remains slower than expected in a highly competitive statin market.
The filing emphasizes extensive risk factors: intense competition and generic pressure on AGGRASTAT and ZYPITAMAG, reliance on third-party manufacturers, heavy regulation of pharmaceuticals and pharmacies, product liability exposure, environmental and workplace compliance, foreign-exchange risk from U.S.-dollar revenues, potential need for additional capital, share-price volatility, possible PFIC-related U.S. tax issues, and financial impact from U.S. policy changes under the Inflation Reduction Act, including assessed penalties.